SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2016
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrant’s name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x | Form 40-F ¨ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ | No x |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
On February 17, 2016, Fresenius Medical Care AG & Co. KGaA (the “Company”) issued an Investor News announcing an agreement in principle to resolve the GranuFlo®/NaturaLyte® product liability litigation.
EXHIBITS
Exhibit 99.1 Investor News Release issued February 17, 2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: February 18, 2016
| FRESENIUS MEDICAL CARE AG & Co. KGaA, | ||
| a partnership limited by shares, represented by: | ||
|
| ||
| FRESENIUS MEDICAL CARE MANAGEMENT AG, its | ||
| general partner | ||
|
|
| |
|
|
| |
| By: | /s/ RICE POWELL | |
|
| Name: | Rice Powell |
|
| Title: | Chief Executive Officer and |
|
|
| Chairman of the Management Board |
|
|
| of the General Partner |
|
|
|
|
|
|
| |
| By: | /s/ MICHAEL BROSNAN | |
|
| Name: | Michael Brosnan |
|
| Title: | Chief Financial Officer and member |
|
|
| of the Management Board of the |
|
|
| General Partner |